Abstract
As first-generation antisense oligonucleotides, more than a dozen phosphorothioate oligodeoxynucleotides (PS ODNs) have been clinically developed, but only one has reached the market. To improve the drawbacks of PS ODNs, such as low affinity to target mRNA and non-specific binding to proteins, modified oligonucleotides with 2-modified sugars such as 2-O-(2-methoxy)ethyl and 2-F modification or with bridged sugars such as oxyalkylene linkages between 2-oxygen and 4-carbon, have been synthesized as 2-MOE, 2-F RNA, 2,4-BNA/LNA and ENA oligonucleotides. They have shown properties of higher affinity to complementary single-stranded RNA and DNA than those of PS ODNs due to their preorganized N-conformation. On the basis of the properties of these newly designed oligonucleotides, their in vitro and in vivo applications for gene silencing as true antisense oligonucleotides have been reported. In this review, antisense applications with these modified oligonucleotides are focused on.
Keywords: DNA oligonucleotides, bridged nucleosides, Gapmers, Duchenne muscular dystrophy, RNA polymerase II
Current Topics in Medicinal Chemistry
Title: True Antisense Oligonucleotides with Modified Nucleotides Restricted in the Nconformation
Volume: 7 Issue: 7
Author(s): Makoto Koizumi
Affiliation:
Keywords: DNA oligonucleotides, bridged nucleosides, Gapmers, Duchenne muscular dystrophy, RNA polymerase II
Abstract: As first-generation antisense oligonucleotides, more than a dozen phosphorothioate oligodeoxynucleotides (PS ODNs) have been clinically developed, but only one has reached the market. To improve the drawbacks of PS ODNs, such as low affinity to target mRNA and non-specific binding to proteins, modified oligonucleotides with 2-modified sugars such as 2-O-(2-methoxy)ethyl and 2-F modification or with bridged sugars such as oxyalkylene linkages between 2-oxygen and 4-carbon, have been synthesized as 2-MOE, 2-F RNA, 2,4-BNA/LNA and ENA oligonucleotides. They have shown properties of higher affinity to complementary single-stranded RNA and DNA than those of PS ODNs due to their preorganized N-conformation. On the basis of the properties of these newly designed oligonucleotides, their in vitro and in vivo applications for gene silencing as true antisense oligonucleotides have been reported. In this review, antisense applications with these modified oligonucleotides are focused on.
Export Options
About this article
Cite this article as:
Koizumi Makoto, True Antisense Oligonucleotides with Modified Nucleotides Restricted in the Nconformation, Current Topics in Medicinal Chemistry 2007; 7 (7) . https://dx.doi.org/10.2174/156802607780487768
DOI https://dx.doi.org/10.2174/156802607780487768 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Efficacy and Cardiovascular Safety of Insulins
Current Drug Safety 99mTc-(tricine)-HYNIC-Lys-FROP Peptide for Breast Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Oxopyrido[2,3-d] Pyrimidine-7- ones Derivatives as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors
Letters in Drug Design & Discovery Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy A Bioinformatics Pipeline for Cancer Epigenetics
Current Bioinformatics Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the Approaching Wave of “Proteomics Diagnostics”
Current Pharmacogenomics and Personalized Medicine Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Microarray Data Integration: Frameworks and a List of Underlying Issues
Current Bioinformatics MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design